Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2020-02-19 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 147.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Notice under Section 708A of the Corporations Act' related to the issuance of shares by HeraMED Limited. It references the Corporations Act 2001 and details the issuance of 500,000 shares without disclosure under Part 6D.2 of the Act. The document is short (2750 characters) and serves as a formal notice of a capital raising event rather than a full financial report or detailed analysis. It does not contain financial statements or substantive financial data but rather a regulatory notice about share issuance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2020-02-19 English
Results of General Meeting 3 pages 143.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 19 February 2020 reporting the results of a General Meeting held by HeraMED Limited. It includes detailed proxy voting results for various resolutions passed at the meeting. The text references the Corporations Act 2001 and provides voting outcomes, which is typical for a Declaration of Voting Results document. There is no indication that this is a full report like an Annual Report or Interim Report, nor is it a proxy solicitation or management discussion. The document is about the official results from shareholder votes at a general meeting, matching the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5294 characters, sufficient to include detailed voting results rather than just a brief announcement. Therefore, the correct classification is DVA with high confidence.
2020-02-18 English
Proposed issue of Securities - HMD 6 pages 31.5KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Heramed Limited. It details the number and types of securities to be issued, the purpose of the issue, approval status, and other related information. There is no financial performance data, management discussion, or audit information. The content focuses on the capital raising activity and issuance of new shares and options. This fits the definition of a Capital/Financing Update (CAP). The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2020-02-18 English
Appendix 2A 16 pages 259.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, and references to ASX Listing Rules and related regulatory requirements. This type of document is a regulatory announcement related to capital markets activity, specifically the application for quotation of new securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document is a formal regulatory filing notifying the market and ASX of a securities quotation application, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit into more specific categories like Capital/Financing Update or Share Issue/Capital Change. Although it relates to securities issuance, it is an application for quotation rather than an announcement of a share issue or capital change itself, so it is best classified as Regulatory Filings (RNS). The document length is substantial (15,000 characters), so it is not a brief announcement. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2020-02-18 English
HeraBEAT Plus Clinical Trial Study Details 2 pages 188.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 17 February 2020 providing details about an upcoming clinical trial by HeraMED Limited. It describes the study design, inclusion and exclusion criteria, and the purpose of the trial. There are no financial statements, earnings data, or management discussion of financial results. The document is informational about a clinical trial and does not fit into financial report categories such as Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing, board change, or capital update. The document is a company announcement providing additional details about a previously announced clinical trial, which aligns best with a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2020-02-16 English
Mayo Clinic clinical study to evaluate HeraBEAT Plus 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 February 2020 about Mayo Clinic launching a clinical study to evaluate HeraMED's HeraBEAT Plus device. It is a corporate news release about a clinical study initiation and does not contain financial data, regulatory filings, or report publication information. The document is short (3074 characters) and is clearly an announcement rather than a detailed report or financial filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about a clinical study, which is best classified under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2020-02-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.